Amôr et al. [23] found that IL33 expression was significantly correlated with the poor prognosis of tongue cancer, suggesting that IL33-mediated malignant progression may activate the downstream signal ST2, such as nuclear factor-κB, which is a key inducer of innate immunity and inflammation and an important endogenous tumor promoter. The gene discussed is IL33; the disease is tongue cancer.